Conv. Plasma
Nigella Sativa

All curcumin studies
Meta analysis
study COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 89% Improvement Relative Risk Ventilation 75% 2-point improvement 46% Hospitalization time 10% Curcumin  Sankhe et al.  EARLY TREATMENT  RCT Is early treatment with curcumin + combined treatments beneficial for COVID-19? RCT 174 patients in India (October 2020 - March 2021) Improved recovery with curcumin + combined treatments (p=0.002) Sankhe et al., J. Ayurveda and Integra.., Aug 2021 Favors curcumin Favors control

A prospective, multi center, single blind, randomized controlled study evaluating “AyurCoro3” as an adjuvant in the treatment of mild to moderate COVID

Sankhe et al., Journal of Ayurveda and Integrated Medical Sciences, doi:10.21760/jaims.6.4.6
Aug 2021  
  Source   PDF   All   Meta
Curcumin for COVID-19
14th treatment shown to reduce risk in February 2021
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
RCT 174 patients in India, 87 treated with AyurCoro-3 (turmeric, gomutra, potassium alum, khadisakhar, bos indicus milk, ghee), showing faster recovery with treatment. EC/NEW/INST/2019/245.
This is the 5th of 20 COVID-19 RCTs for curcumin, which collectively show efficacy with p=0.0000093.
This is the 8th of 26 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.000000046 (1 in 22 million).
risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 87 (0.0%), control 4 of 87 (4.6%), NNT 22, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 75.0% lower, RR 0.25, p = 0.37, treatment 1 of 87 (1.1%), control 4 of 87 (4.6%), NNT 29.
risk of no 2-point improvement, 46.5% lower, RR 0.54, p = 0.002, treatment 29 of 87 (33.3%), control 60 of 87 (69.0%), NNT 2.8, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, day 7 mid-recovery.
hospitalization time, 10.0% lower, relative time 0.90, p = 0.40, treatment 87, control 87.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sankhe et al., 10 Aug 2021, Randomized Controlled Trial, India, peer-reviewed, 8 authors, study period October 2020 - March 2021, this trial uses multiple treatments in the treatment arm (combined with gomutra, potassium alum, khadisakhar, bos indicus milk, ghee) - results of individual treatments may vary.
This PaperCurcuminAll
A prospective, multi center, single blind, randomized controlled study evaluating "AyurCoro3" as an adjuvant in the treatment of mild to moderate COVID-19 patients
Dr Ajay Prabhakar Sankhe, Nanasaheb Somnath Memane, Vijaykumar P Gawali, Sonal Nanasaheb Memane, Ganesh Ramakrishnan, Mayur Nimba Bagul, Rashmi Tiwari, Vikram Bansal, Ayurveda Head, Dept, Clinical Research Head, Consultant Ayurveda, Somnath Nanasaheb, Vijaykumar P Memane, Gawali, Nanasaheb Sonal, Ganesh Memane, Mayur Nimba Ramakrishnan, Rashmi Bagul, Vikram Tiwari, Bansal
INTRODUCTION The Coronavirus disease (COVID-19) has affected the world worst with over 158 million patients infected
Bombardieri, Easthope, Convergence between orthodox and alternative medicine: A theoretical elaboration and empirical test, Health
Chauhan, Immunomodulatory properties of indigenous cow urine, MOJ Immunol
Chauhan, Semwal, Mishra, Semwal, Ayurvedic research and methodology: Present status and future strategies, Ayu
Consort, Transparent reporting of trials
Goyal, Threats and challenges of emerging viral diseases and scope of Ayurveda in its prevention, AYU
Jennings, Parks, Curcumin as an Antiviral Agent, Viruses
Kim, Lee, Hwang, Kwon, Jung et al., Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells, PLoS One
Payyappallimana, Patwardhan, Mangalath, Kessler, Jayasundar et al., The COVID-19 Pandemic and the Relevance of Ayurveda's Whole Systems Approach to Health and Disease Management, J Altern Complement Med
Randhawa, Sharma, Chemotherapeutic potential of cow urine: A review, J Intercult Ethnopharmacol
Rotti, Raval, Anchan, Bellampalli, Bhale et al., Determinants of Prakriti, the human constitution types of Indian traditional medicine and its correlation with contemporary science, J Ayurveda Integr Med
Semwal, Mishra, Chauhan, Semwal, Adverse health effects of tobacco and role of Ayurveda in their reduction, J Med Sci
Tijare, Ambatkar, Tiwari, Clinical Improvement In COVID19 Patients With Timely Intervention Of Panchagavya Medicine: A Preliminary Finding, Int J of Pharmc Res [Internet
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop